endometrial cancer research hub

A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

This study looks at a new treatment called Selinexor for advanced womb cancer. It aims to see if Selinexor helps patients live longer without their cancer growing after chemotherapy, compared to a dummy pill. It's a key stage of research.

SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study

This study is looking at a new way to find if womb cancer has spread to nearby glands (lymph nodes). It uses a special scan called a PET/CT after injecting a dye. The aim is to see how well this new method works compared to current approaches.

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.

A Study of MGC026 in Participants With Advanced Solid Tumors

This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

This study looks at new drug combinations for advanced or returning endometrial cancer that has a specific HER2 marker. It aims to see if these new treatments work better than standard chemotherapy by slowing down cancer growth.

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

This study looks at new treatments for endometrial cancer based on specific cancer features. It aims to find better ways to treat patients after surgery, potentially leading to personalised care for different types of endometrial cancer.

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

This study is looking into a new medication called ALTA2618 for adults with certain advanced cancers that have a specific genetic change (AKT1 E17K mutation). The main goal is to check its safety and find the right dose.

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

This study is looking at a new treatment called dostarlimab for advanced or recurring endometrial cancer that has a specific genetic feature (MMR deficient). It compares dostarlimab with standard chemotherapy to see which works better and is safer for patients.

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.

Cancer Loyalty Card Study 2 (CLOCS-2)

This study looks at shopping habits using loyalty card data from Tesco or Boots to see if certain purchases might hint at cancer earlier. It aims to help doctors diagnose pancreatic, bowel, oesophageal, stomach, liver, bladder, womb, vulval, and ovarian cancers sooner.

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

This study looks at a new drug, sacituzumab govitecan, for women with endometrial cancer that has come back or hasn't responded to earlier treatments. It compares this new drug to standard treatments chosen by doctors, aiming to see if it helps women live longer or keeps cancer from growing.

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

This study is testing a new medicine called AZD8205, by itself or with other cancer drugs. It's for people with advanced cancers like breast, ovarian, or lung cancer, to see if it's safe and helps shrink tumours.

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

This study is testing a new medicine called MOv18 IgE for women with advanced ovarian, endometrial, or triple-negative breast cancer. It aims to find a safe dose and see how well it works, especially in cancers that have a specific marker called Folate Receptor Alpha.

Methylated Biomarkers Predictive of Endometrial Cancer Risk

This study looks for early signs of womb cancer in women aged 45-70 who are having a hysterectomy. Researchers hope to find new ways to detect cancer risk using simple tests, making diagnosis easier and less invasive in the future.

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.

Performance of Ultrasound in Women With Postmenopausal or Abnormal Uterine Bleeding Between White and Black Ethnic Groups- a Retrospective Cohort Study.

This study looks at how well ultrasound scans work for women with unusual vaginal bleeding, especially after menopause. It compares results between White and Black women to see if there are differences in how clear the scans are, which helps doctors check for womb cancer.

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This study compares a new drug, Puxitatug Samrotecan, with standard chemotherapy for advanced endometrial cancer that has returned after previous treatments. It aims to see if the new drug can help patients live longer or stop their cancer from getting worse.

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.

Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.

This study looks at a new way to take a womb lining sample for women who have bleeding after menopause. It uses ultrasound to guide the doctor, hoping to get a better sample, cause less pain, and speed up treatment compared to the usual method.

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to conventional staging in women with presumed early-stage endometrial cancer (The BIOMEC trial)

A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.